VIVUS Reports Fourth Quarter 2017 Financial Results

VIVUS (NASDAQ: VVUS) a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for the quarter and year ended December 31, 2017 and provided a business update.

As quoted in the press release:

“Throughout 2017, we executed on strategies intended to expand our pipeline and maximize our legacy assets. Achievements in these areas include advancing tacrolimus toward the clinic, with a phase 2 trial start scheduled for the second half of 2018, and our marketing agreement for Qsymia^® in the Republic of Korea,” said Thomas B. King, VIVUS’ interim Chief Executive Officer. “We move into 2018 with continued efforts to monetize our current assets, identify additional assets to enhance our pipeline and financial resources, and ultimately create value for patients and stockholders.”

Click here to read the full press release.